Research programme: protein therapies - CureVac

Drug Profile

Research programme: protein therapies - CureVac

Alternative Names: Protein replacement therapy - CureVac; RNAntibody®; RNArt®protein therapy; Sequence engineered mRNA - CureVac

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Developer Acuitas Therapeutics; CureVac
  • Class Proteins
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Rabies; Unspecified

Most Recent Events

  • 24 Jan 2018 CureVac has patent protection for its RNArt® and RNAntibody® technologies
  • 08 Nov 2016 CureVac has patent protection for RNAntibody® technology in Europe
  • 08 Nov 2016 Preclinical trials in Cancer in Germany (Parenteral) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top